Dyadic's C1-produced RSV, malaria antibodies advance to animal studies
DYAI•Dyadic International's C1-produced RSV and malaria antibodies entered animal studies led by the Gates Medical Research Institute. Seven-day fermentation runs yielded about 12.1 g/L for RSV antibody RSM01 and 13.2 g/L for malaria antibody MAM01; results are expected in the first quarter of 2027.
1. Animal studies begin
Studies comparing the pharmacokinetics of C1-produced antibodies with mammalian-cell-produced counterparts began October 20, 2026, across four groups of mice. The Gates Medical Research Institute is leading the studies, with results expected in the first quarter of 2027.
2. Fermentation yields
Seven-day fermentation runs yielded approximately 12.1 g/L for RSV antibody RSM01 and 13.2 g/L for malaria antibody MAM01.
